Memory CD4 helper T cells and antibody production following renal transplantation
肾移植后记忆 CD4 辅助 T 细胞和抗体产生
基本信息
- 批准号:9283290
- 负责人:
- 金额:$ 39.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-08 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAlloantigenAllograftingAnimal ModelAntibodiesAntibody FormationAntigensAutoantibodiesAutoimmunityB-LymphocytesBiological AssayBlood capillariesBortezomibC57BL/6 MouseCD4 Positive T LymphocytesChronicClinicalClinical ResearchCollagen Type IVComplement InactivatorsCreatinineCytokine Network PathwayDataDepositionDiagnosticFibronectinsFundingGenerationsGoalsGraft RejectionHeart TransplantationHelper-Inducer T-LymphocyteHistologicHumanImmune responseImmunityImmunosuppressionInfiltrationInflammationInjuryIntravenous ImmunoglobulinsInvestigationIsoantibodiesKidneyKidney TransplantationKineticsLungLung TransplantationLymphoidMHC Class I GenesMHC Class II GenesMS4A1 geneMaintenanceMediatingMemoryMolecularOrganOrgan TransplantationOutcomePathogenicityPathway interactionsPatientsPhenotypePhysiologicalPlasma CellsPlasmapheresisPreventionProductionPropertyProteasome InhibitorResistanceRodent ModelRoleSerumSignal TransductionSpecificitySplenectomyStructure of germinal center of lymph nodeT cell responseT memory cellT-LymphocyteTNFRSF5 geneTNFSF5 geneTestingTissue GraftsTissuesTransplant RecipientsTransplantationallograft rejectionautoreactive B cellcapillaryclinically relevantcomplement C4dcourse developmentcytokinegraft functionheart allografthigh riskinhibiting antibodykidney allograftmemory CD4 T lymphocytemouse modelpreventresponserituximabscreeningsuccesstargeted treatmenttositumomabtrafficking
项目摘要
Project Summary / Abstract
Despite advances in immunosuppression and routine PRA screening prior to transplantation, acute and
chronic antibody-mediated rejection (AMR) undermine long-term survival of transplanted organs. The success
of therapies targeting AMR in transplant patients is limited by the incomplete understanding of the mechanisms
underlying DSA and autoantibody generation and functions. Previous studies of humoral responses following
transplantation were impeded by the lack of reliable assays to detect allo- and autoreactive B cells and by the
paucity of physiologically relevant animal models of AMR. Production of pathogenic allo- and autoantibodies
requires interactions between B cells and activated helper CD4 T cells. The T cell repertoire of many humans
includes alloreactive memory T cells that are resistant to immunosuppression or costimulatory blockade.
During the previous funding cycle, we demonstrated that memory CD4 T cells induce superior donor-specific
alloantibody (DSA) responses compared to primary effector CD4 T cells. We have developed physiologically
and clinically relevant mouse models of acute and chronic AMR to investigate the mechanisms of allo- and
autoantibody generation after kidney transplantation. Our preliminary data show that donor-reactive memory
CD4 T cells induce robust DSA and autoantibody responses in renal allograft recipients resulting in acute
AMR. In contrast to de novo DSA, autoantibody generation is not prevented by anti-CD20 antibody treatment
and is associated with chronic graft tissue injury. The goal of this project is to determine helper signals required
for generation of pathogenic allo- and autoantibodies and to use this information to inhibit AMR in sensitized
renal allograft recipients. We hypothesize that the molecular requirements for allo- and autoantibody
production following renal transplantation and the specificity and pathogenicity of resulting antibody are
determined by the functional phenotype of helper CD4 T cells and by the intensity of post-transplant
inflammation. We will test this hypothesis in three Specific Aims:
Aim 1. To determine helper requirements for the production and maintenance of donor MHC class I- and MHC
class II-specific DSA and collagen IV- and fibronectin-specific autoantibodies in renal transplant recipients.
Aim 2. To test the role of BAFF/APRIL cytokine network during the generation of pathogenic allo- and
autoantibodies in renal allograft recipients.
Aim 3. To test the effects of post-transplant inflammation on the generation of allo- and autoantibodies
following renal transplantation.
项目摘要/摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Anna Valujskikh其他文献
Anna Valujskikh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Anna Valujskikh', 18)}}的其他基金
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10357956 - 财政年份:2021
- 资助金额:
$ 39.62万 - 项目类别:
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10228265 - 财政年份:2021
- 资助金额:
$ 39.62万 - 项目类别:
Mechanisms of alloantibody production following renal transplantation
肾移植后同种抗体产生的机制
- 批准号:
10551197 - 财政年份:2021
- 资助金额:
$ 39.62万 - 项目类别:
Designing induction therapies to target memory T cells in high risk recipients
设计针对高危受者记忆 T 细胞的诱导疗法
- 批准号:
9027079 - 财政年份:2015
- 资助金额:
$ 39.62万 - 项目类别:
Designing induction therapies to target memory T cells in high risk recipients
设计针对高危受者记忆 T 细胞的诱导疗法
- 批准号:
9193613 - 财政年份:2015
- 资助金额:
$ 39.62万 - 项目类别:
Designing induction therapies to target memory T cells in high risk recipients
设计针对高危受者记忆 T 细胞的诱导疗法
- 批准号:
10682434 - 财政年份:2014
- 资助金额:
$ 39.62万 - 项目类别:
Designing induction therapies to target memory T cells in high risk recipients
设计针对高危受者记忆 T 细胞的诱导疗法
- 批准号:
8878467 - 财政年份:2014
- 资助金额:
$ 39.62万 - 项目类别:
Designing induction therapies to target memory T cells in high risk recipients
设计针对高危受者记忆 T 细胞的诱导疗法
- 批准号:
10362129 - 财政年份:2014
- 资助金额:
$ 39.62万 - 项目类别:
CD4 Memory T Cells and Allograft Rejection
CD4 记忆 T 细胞和同种异体移植排斥
- 批准号:
8078592 - 财政年份:2010
- 资助金额:
$ 39.62万 - 项目类别:
Memory CD4 T cell driven antibody responses to renal allografts
记忆 CD4 T 细胞驱动的抗体对肾同种异体移植物的反应
- 批准号:
7891954 - 财政年份:2010
- 资助金额:
$ 39.62万 - 项目类别:
相似海外基金
Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
- 批准号:
23K08289 - 财政年份:2023
- 资助金额:
$ 39.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10432434 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
- 批准号:
10744193 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
- 批准号:
10534556 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
- 批准号:
10612453 - 财政年份:2022
- 资助金额:
$ 39.62万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10204102 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10443701 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10737340 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
- 批准号:
10652374 - 财政年份:2019
- 资助金额:
$ 39.62万 - 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
- 批准号:
9005358 - 财政年份:2016
- 资助金额:
$ 39.62万 - 项目类别:














{{item.name}}会员




